Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-01-11 00:00:00 ET · period of report 2023-01-09 · accession 0000899243-23-001626 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-11 | 2023-01-09+ | VRDN | Katz Barrett | Chief Medical Off | M - OptEx | $23.03 | +60.0K | 47.4K | New | +$1.38M |
| DM | 2023-01-11 | 2023-01-09+ | VRDN | Katz Barrett | Chief Medical Off | S - Sale+OE | $34.82 | -60.0K | 0 | -100% | -$2.09M |
| DM | 2023-01-11 | 2023-01-09+ | VRDN | Katz Barrett | Chief Medical Off | M - OptEx | $0.00 | -60.0K | 343.4K | -15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-09 | M | A | 12,623 | $23.03 | 12,623 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-10 | M | A | 47,377 | $23.03 | 47,377 | D | — | — | |
| 3 | Common | Common Stock | 2023-01-09 | S | D | 12,623 | $33.04 | 0 | D | — | — | |
| 4 | Common | Common Stock | 2023-01-10 | S | D | 47,377 | $35.30 | 0 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-01-10 | M | D | 47,377 | $0.00 | 296,000 | D | $23.03 · — to 2031-01-17 | 47,377 Common Stock | (F3) The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-01-09 | M | D | 12,623 | $0.00 | 343,377 | D | $23.03 · — to 2031-01-17 | 12,623 Common Stock | (F3) The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |